09/03/2026 Pfizer announced Phase 2 results of tilrekimig in AD Pfizer announced Phase 2 results of tilrekimig in AD ( Ref ) Pfizer announced positive topline results from its Phase 2 study that evaluated tilrekimig (PF-07275315; trispecific antibody targets Il-4, IL-13 and TSLP) for the treatment of adult patients with moderate to severe atopic dermatitis (AD) The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of particip

06/03/2026 The US FDA approved deucravacitinib for the treatment of patients with active PsA Aisa Pharma announced the results from its Phase 2 trial of AISA-021 in patients with SSc RP The US FDA approved deucravacitinib for the treatment of patients with active PsA ( Ref ) BMS announced that the US FDA had approved Sotyktu® (deucravacitinib; TYK2 inhibitor) for the treatment of adult patients with active psoriatic arthritis (PsA) The approval was based on positive results f

03/03/2026 UCB and Antengene entered into a global license agreement for ATG-201 targeting B cell-related autoimmune diseases Johnson & Johnson received US FDA fast track designation for nipocalimab in SLE Priovant’s brepocitinib received US FDA acceptance and priority review for patients with dermatomyositis COUR Pharma announced Phase 2a results of CNP-104 in PBC Kyowa Kirin announced the discontinuation of rocatinlimab clinical trials UCB and Antengene entered into a globa